Should device replacement be the first choice strategy in continuous-flow left ventricle assist device thrombosis? Analysis of 9 events and results after endoventricular thrombolysis

Int J Cardiol. 2015 Jan 15:178:159-61. doi: 10.1016/j.ijcard.2014.10.169. Epub 2014 Oct 28.

¹ Cardiac Surgery and Heart Transplantation Unit, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, Italy. Electronic address: giuseppe.raffa78@gmail.com.
² Cardiac Surgery and Heart Transplantation Unit, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, Italy.
³ Cardiology Unit, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, Italy.
⁴ Statistical Office, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, Italy.
⁵ Management Control and Decision Support, University of Pittsburgh Medical Center Italy (UPMC Italy), Palermo, Italy.

No abstract available

Keywords: CF-LVAD thrombosis; Health econo; HeartWare HVAD; Outcomes; Thrombolysis.

Publication types